ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Bayer To Develop Cancer Treatment With Amgen

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. MAIN FACTS: -Financial details of the deal weren't disclosed. -Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. -After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate. -In 2009, Bayer had entered into an agreement with Micromet, Inc. to produce another antibody. -Micromet was acquired by Amgen in early 2012. -Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
01/19/201717:29:35Amended Statement of Ownership (sc 13g/a)
01/17/201710:00:00deCODE Study Shows that Variants in the Sequence of the Genome...
01/17/201705:00:00deCODE Study Shows that Variants in the Sequence of the Genome...
01/13/201717:17:58Post-effective Amendment to an S-8 Filing (s-8 Pos)
01/13/201717:11:28Post-effective Amendment to an S-8 Filing (s-8 Pos)
01/13/201716:21:00Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech...
01/10/201716:12:00Study Results Published in the Journal of the American Medical...
01/09/201718:21:00Amgen Statement on January 9, 2017, U.S. District Court Decision
01/09/201706:12:09Current Report Filing (8-k)
01/09/201706:00:00Amgen And DaVita Enter Into New Sourcing And Supply Agreement
01/09/201704:00:00Amgen and Immatics Enter Strategic Collaboration to Develop Novel...
01/06/201714:29:00Sanofi Investors Count Cost of Praluent Ruling -- Update
01/06/201708:41:00Sanofi Investors Count Cost of Praluent Ruling
01/06/201703:02:00Sanofi Loses Patent Case -- WSJ
01/05/201721:34:00Court Grants Permanent Injunction For Infringement Of Amgen's...
01/05/201721:07:00Judge Rules Against Sanofi and Regeneron in Patent Case -- Update
01/05/201720:25:00Judge Rules Against Sanofi and Regeneron in Patent Case
01/04/201716:00:00Amgen To Present At The 35th Annual J.P. Morgan Healthcare Conference
12/22/201619:27:00Donald Trump's Pick for Health Secretary Traded Medical Stocks...
12/20/201616:20:00Amgen Announces 15 Percent Increase In 2017 First Quarter Dividend

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US